ONCY

Oncolytics Biotech Inc. (ONCY) | Rumor.io

Oncolytics Biotech

ONCY

Attention (50-day avg)0%

Attention rank (50-day avg)#891

Bullish sentiment (50-day avg)91%

Price to earnings ratio-2.23

Market capitalization84.2M

Earnings per share-0.35

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-28.8M

Social

What share of all stock conversation is about ONCY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 25

Oncolytics Biotech Inc. ($ONCY) is in late-stage partnership discussions for its cancer treatment asset SCAC, with hopes of making an announcement soon.
A potential partnership would involve using the partner's product, but the financial terms of the deal are unclear.
Oncolytics' share price has increased in recent months, but insiders have not been buying shares, sparking concerns about material insider information.

Generated by AI

Sentiment

Of the messages about ONCY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	54.55% -45.45	87.85% -4.19	84.03% +9.3
Bearish	—	45.45% +45.45	12.15% +4.19	15.97% -9.3

Bullish· Feb 13

Oncolytics Biotech has a strong buy analyst consensus rating with a $5.50 average price target, representing a 570.7% upside.
The company's re-domiciling is nearing conclusion, which could lead to significant developments and interest in the stock.
Recent insider purchases, including a group buy of 3.5 million shares, suggest that the company's management and investors are optimistic about its future prospects.

Bearish· Jun 20

Oncolytics Biotech Inc. ($ONCY) has a history of spam and unsubstantiated claims on its message board, with one user, notable_ex, being an admitted paid pumper with no long position in the company.
Notable_ex claims that Merck and Roche are not interested in Oncolytics' cancer immunotherapy, pelareorep, which may impact the company's potential partnerships and revenue.
Oncolytics Biotech Inc. ($ONCY) has been accused of building a 20-year portfolio fortress, which may indicate a lack of short-term focus and potential for long-term stagnation.

Generated by AI

Topics

Of the messages about ONCY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	67.26%	11.5%
Earnings	—	0%	0%	0.03%
Analysts	—	0%	5.31%	13.22%
Technical Analysis	—	0%	27.43%	1.35%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	73.9%

Announcements· Aug 19

Oncolytics Biotech Inc. is developing pelareorep, an IV oncolytic reovirus designed to turn "cold" tumors into "hot" tumors, with promising clinical data in pancreatic, colorectal, and anal cancers.
The FDA has provided written feedback aligning on a potential registrational path for pelareorep in 2L RAS-mutant MSS metastatic colorectal cancer, with the possibility of expanding into a pivotal Part B study.
Oncolytics Biotech has partnered with major pharmaceutical companies, including Roche, Pfizer, and Merck Serono, to expand the development of pelareorep without funding every study alone, with a diversified clinical pipeline giving investors multiple shots on goal.

Technical Analysis· Feb 17

The 15-minute chart for ONCY shows a narrowing range, suggesting a potential upward move before noon.
A double bottom pattern has formed, and breaking above $3.08 is expected to lead to further gains, with potential targets at $3.21, $3.45, and beyond.
The stock has shown gains in premarket trading, with a solid base forming, and a cup and handle pattern developing, indicating a potential breakout.

Generated by AI

Community

Of the messages about ONCY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	87.5%	69.47%	15.98%
Newcomers	0%	12.5%	30.53%	84.02%

Regulars· Sep 25

A new HC Wainwright interview with JK mentions "late stage partnership discussions" for SCAC, with the potential for a partnership involving the partner's product, but no mention of financial involvement.
Insiders are not buying shares, suggesting there may be material information that is not being disclosed, preventing them from taking advantage of the stock.
The stock's "FAILED-TO-DELIVER" stats on shorted shares that failed to deliver are seen as confirmation of a long-running short selling tax harvesting scheme by certain parties.

Newcomers· Aug 19

Oncolytics Biotech's pelareorep is an IV oncolytic reovirus designed to turn "cold" tumors into "hot" tumors, with promising data in pancreatic, colorectal, and anal cancers.
The company has received written FDA feedback aligning on a potential registrational path for pelareorep in 2L RAS-mutant MSS metastatic colorectal cancer, supporting a potential accelerated approval pathway.
Oncolytics Biotech's clinical pipeline is diversified, with pelareorep being studied in multiple GI cancers, and collaborations with major pharma companies, including Roche, Pfizer, and Merck Serono, expanding the program without significant funding requirements.

Generated by AI

Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected

2d agoYahoo Finance

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.

14d agoYahoo Finance

Oncolytics reports preclinical data on pelareorep with RAS inhibitor

19d agoInvesting.com

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

20d agoYahoo Finance

ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Alignment Reached with FDA on Potential Registrational Pathway in CRC On August 18, 2026, Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced it had received written feedback from the FDA regarding the potential expansion of the ongoing REO 033 trial into a pivotal Part B study. REO 033 is a randomized study

1mo agoYahoo Finance

Also Discussed

Investors talking about ONCY also mention

#	Name	Attention
1	GENE - Genetic Technologies Limited	——
2	CTIC - CTI BioPharma Corp.	——
3	Agenus Inc.AGEN	0.01%-0.01
4	AEZS - Aeterna Zentaris Inc.	——
5	Ainos, Inc.AIMD	0%+0
6	DNP Select Income Fund Inc.DNP	0%new
7	Rein Therapeutics Inc.RNTX	0%0
8	Veea Inc.VEEA	0%0
9	CleanCore Solutions Inc. Class B Common StockZONE	0%+0
10	Envoy Medical Inc Class A Common StockCOCH	0%0

Oncolytics Biotech Inc.

Healthcare
Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer. The company’s current programs center on solid tumors and hematological malignancies, with particular emphasis on gastrointestinal cancers such as colorectal, pancreatic, and anal cancers, as well as hormone receptor-positive, HER2-negative breast cancer. Its research approach combines pelareorep with chemotherapy and immune checkpoint inhibitors to improve how tumors respond to treatment. Oncolytics Biotech also advances clinical studies and regulatory development efforts through its pipeline and strategic collaborations, positioning the company within the oncology immunotherapy market.

Website

Location

4350 Executive Drive

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about ONCY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 25

Oncolytics Biotech Inc. ($ONCY) is in late-stage partnership discussions for its cancer treatment asset SCAC, with hopes of making an announcement soon.
A potential partnership would involve using the partner's product, but the financial terms of the deal are unclear.
Oncolytics' share price has increased in recent months, but insiders have not been buying shares, sparking concerns about material insider information.

Generated by AI

Sentiment

Of the messages about ONCY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	54.55% -45.45	87.85% -4.19	84.03% +9.3
Bearish	—	45.45% +45.45	12.15% +4.19	15.97% -9.3

Bullish· Feb 13

Oncolytics Biotech has a strong buy analyst consensus rating with a $5.50 average price target, representing a 570.7% upside.
The company's re-domiciling is nearing conclusion, which could lead to significant developments and interest in the stock.
Recent insider purchases, including a group buy of 3.5 million shares, suggest that the company's management and investors are optimistic about its future prospects.

Bearish· Jun 20

Oncolytics Biotech Inc. ($ONCY) has a history of spam and unsubstantiated claims on its message board, with one user, notable_ex, being an admitted paid pumper with no long position in the company.
Notable_ex claims that Merck and Roche are not interested in Oncolytics' cancer immunotherapy, pelareorep, which may impact the company's potential partnerships and revenue.
Oncolytics Biotech Inc. ($ONCY) has been accused of building a 20-year portfolio fortress, which may indicate a lack of short-term focus and potential for long-term stagnation.

Generated by AI

Topics

Of the messages about ONCY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	67.26%	11.5%
Earnings	—	0%	0%	0.03%
Analysts	—	0%	5.31%	13.22%
Technical Analysis	—	0%	27.43%	1.35%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	73.9%

Announcements· Aug 19

Oncolytics Biotech Inc. is developing pelareorep, an IV oncolytic reovirus designed to turn "cold" tumors into "hot" tumors, with promising clinical data in pancreatic, colorectal, and anal cancers.
The FDA has provided written feedback aligning on a potential registrational path for pelareorep in 2L RAS-mutant MSS metastatic colorectal cancer, with the possibility of expanding into a pivotal Part B study.
Oncolytics Biotech has partnered with major pharmaceutical companies, including Roche, Pfizer, and Merck Serono, to expand the development of pelareorep without funding every study alone, with a diversified clinical pipeline giving investors multiple shots on goal.

Technical Analysis· Feb 17

The 15-minute chart for ONCY shows a narrowing range, suggesting a potential upward move before noon.
A double bottom pattern has formed, and breaking above $3.08 is expected to lead to further gains, with potential targets at $3.21, $3.45, and beyond.
The stock has shown gains in premarket trading, with a solid base forming, and a cup and handle pattern developing, indicating a potential breakout.

Generated by AI

Community

Of the messages about ONCY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	87.5%	69.47%	15.98%
Newcomers	0%	12.5%	30.53%	84.02%

Regulars· Sep 25

A new HC Wainwright interview with JK mentions "late stage partnership discussions" for SCAC, with the potential for a partnership involving the partner's product, but no mention of financial involvement.
Insiders are not buying shares, suggesting there may be material information that is not being disclosed, preventing them from taking advantage of the stock.
The stock's "FAILED-TO-DELIVER" stats on shorted shares that failed to deliver are seen as confirmation of a long-running short selling tax harvesting scheme by certain parties.

Newcomers· Aug 19

Oncolytics Biotech's pelareorep is an IV oncolytic reovirus designed to turn "cold" tumors into "hot" tumors, with promising data in pancreatic, colorectal, and anal cancers.
The company has received written FDA feedback aligning on a potential registrational path for pelareorep in 2L RAS-mutant MSS metastatic colorectal cancer, supporting a potential accelerated approval pathway.
Oncolytics Biotech's clinical pipeline is diversified, with pelareorep being studied in multiple GI cancers, and collaborations with major pharma companies, including Roche, Pfizer, and Merck Serono, expanding the program without significant funding requirements.

Generated by AI

Oncolytics Biotech

Social

Sep 25

Bullish· Feb 13

Bearish· Jun 20

Announcements· Aug 19

Technical Analysis· Feb 17

Regulars· Sep 25

Newcomers· Aug 19

Oncolytics reports pelareorep data in liver cancer study

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

Oncolytics reports preclinical data on pelareorep with RAS inhibitor

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

Also Discussed

Oncolytics Biotech Inc.

Company Information

Location

Social

Sep 25

Bullish· Feb 13

Bearish· Jun 20

Announcements· Aug 19

Technical Analysis· Feb 17

Regulars· Sep 25

Newcomers· Aug 19

Oncolytics reports pelareorep data in liver cancer study

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

Oncolytics reports preclinical data on pelareorep with RAS inhibitor

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

Also Discussed